Nanocrystal News and Research

RSS

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Novel nanomaterials derived from cellulose have many promising industrial applications, are biobased and biodegradable, and can be produced at relatively low cost. Their potential toxicity--whether ingested, inhaled, on contact with the skin, or on exposure to cells within the body--is a topic of intense discussion, and the latest evidence and insights on cellulose nanocrystal toxicity are presented in a Review article in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

20 Feb 2015

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014

Luminescent nanocrystals tags with high-speed scanning technology detects multiple viruses within minutes

A research team using tunable luminescent nanocrystals as tags to advance medical and security imaging have successfully applied them to high-speed scanning technology and detected multiple viruses within minutes.

9 May 2014

A window to the brain: an interview with Professor Guillermo Aguilar, UC Riverside's Bourns College of Engineering (BCOE)

It is literally a transparent window made of yttria-stabilized zirconia (YSZ), which we envision to become a suitable cranial implant that allows physicians for optical access to the tissue brain. It would serve the same mechanical function of current cranial implants made of other materials, such as titanium, except that it would enable optical access too, which could be very beneficial for post-operatory diagnostic or therapeutic procedures.

8 Oct 2013

Study suggests silicon nanocrystals may be safe tool for diagnostic imaging in humans

Tiny silicon crystals caused no health problems in monkeys three months after large doses were injected, marking a step forward in the quest to bring such materials into clinics as biomedical imaging agents, according to a new study.

1 Aug 2013

Metallurgists use microwave oven to produce nanocrystal semiconductors

University of Utah metallurgists used an old microwave oven to produce a nanocrystal semiconductor rapidly using cheap, abundant and less toxic metals than other semiconductors. They hope it will be used for more efficient photovoltaic solar cells and LED lights, biological sensors and systems to convert waste heat to electricity.

6 May 2013

Scientists develop super-sensitive test that could detect diseases earlier

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

ACS symposium focuses on biomimetics

Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.

27 Mar 2012

New process can create LEDs that produce light in the UV range

A multinational team of scientists has developed a process for creating glass-based, inorganic light-emitting diodes (LEDs) that produce light in the ultraviolet range. The work, reported this week in the online Nature Communications, is a step toward biomedical devices with active components made from nanostructured systems.

27 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

Elan's third quarter total revenue increases 17% to $328.5 million

Elan Corporation, plc today reported its third quarter and first nine months 2011 financial results.

27 Oct 2011

Decline of citrate concentration may contribute to bone brittleness

Bone is one of nature's surprising "building materials." Pound-for-pound it's stronger than steel, tough yet resilient. Scientists at the U.S. Department of Energy's Ames Laboratory have identified the composition that gives bone its outstanding properties and the important role citrate plays, work that may help science better understand and treat or prevent bone diseases such as osteoporosis.

9 Jun 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

Life Technologies announces early stage results from SMS technology

Life Technologies Corporation today announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

2 Mar 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Approval of injectable formulation using NanoCrystal technology announced

Elan Drug Technologies, a business unit of Elan Corporation, plc announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.

14 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009